The handoff from a computational drug discovery team to a contract research organization is, in practice, surprisingly painful. Data that was clean and structured inside BioMate becomes a negotiation about file formats, a chain of email attachments, and a set of manual QC checks at the CRO's intake desk — adding days to a process that should take hours.
The Hidden Cost of the CRO Handoff
When a computational team finishes lead optimization and is ready to hand compounds to a CRO for in vitro or in vivo validation, they typically need to export compound structures as SDF files, ADMET predictions as PDFs or spreadsheets, assay specifications as a separate document, and QC records as yet another file. The CRO then reassembles these into its own internal format. Every translation step is an opportunity for error and a source of delay.
For organizations running multiple CRO relationships in parallel — a common pattern in drug discovery — the overhead multiplies. Each CRO has different intake requirements, different preferred formats, and different naming conventions. Managing this manually is a real cost that rarely shows up in project timelines but reliably delays them.
What a Structured Package Looks Like
BioMate generates CRO submission packages that consolidate everything a contract organization needs to begin work: compound records with structures in standard chemical formats, ADMET predictions with confidence assessments, target binding predictions with pose files, relevant QC records from the computational work, and assay specifications generated from the compound's predicted property profile. The full package is assembled in a format that major CROs consume directly — reducing or eliminating the reformatting step at intake.
"A structured handoff is not just faster — it is more accurate. The data that enters the CRO is the same data that came out of BioMate, with no translation layer where information can be lost."
Audit Trail Included
Every element of the submission package is traceable to its source in BioMate's audit trail. The ADMET predictions are linked to the model version and parameters used. The structural data is linked to the generative run that produced it. The QC records are linked to the thresholds that were applied. If a CRO result comes back inconsistent with the computational predictions and the question arises of what the original computational data said, the answer is always available and unambiguous.
Further reading: FDA Investigational New Drug application guidance, PubChem compound database (NIH), ICH multidisciplinary guidelines, and ChEMBL bioactivity database (EBI).
The CRO handoff becomes a file transfer rather than a project. Data that was structured inside BioMate stays structured all the way through intake at the CRO — with fewer errors, less delay, and a complete audit trail connecting the computational prediction to the experimental follow-up.